Crinetics (CRNX) announced the submission of a marketing authorization application to Brazil’s National Health Surveillance Agency, or ANVISA, for Palsonify, the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment of acromegaly in adults.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics Advances Atumelnant: Phase 1 Study Completion Sets Up Next Clinical Catalyst for CRNX
- Crinetics Pharma Earnings Call: Launch, Pipeline, Runway
- Crinetics price target lowered to $96 from $105 at Citizens
- Crinetics price target lowered to $83 from $84 at Stifel
- Crinetics reports Q4 EPS ($1.29), consensus ($1.37)